Abstract: AZD5363, widely known as Capivasertib, is a potent, orally bioavailable, ATP-competitive pan-AKT inhibitor. The deregulation of the PI3K-AKT-mTOR signaling pathway, frequently driven by PTEN loss of function, plays a critical role in the development, progression, and treatment resistance of prostate cancer. Capivasertib has been developed to target this pathway by inhibiting all three AKT isoforms, thereby disrupting cellular proliferation, glucose metabolism, and survival signals, while promoting apoptosis. In recent and ongoing clinical trials, including the ProCAID and CAPItello-281 studies, Capivasertib has demonstrated significant clinical activity in prostate cancer, particularly in improving overall survival in metastatic castration-resistant prostate cancer (mCRPC) and radiographic progression-free survival in PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC). Despite its promising efficacy, the clinical utility of Capivasertib is accompanied by on-target toxicities such as rash, hyperglycemia, and diarrhea. Current research is heavily focused on biomarker-driven patient selection and rational combination strategies with androgen deprivation therapies to maximize therapeutic outcomes.
1. Introduction
The deregulation of the PI3K-Akt-mTOR signaling pathway plays a critical role in the development and progression of numerous human malignancies, including prostate cancer [1]. The Akt protein, also known as protein kinase B (PKB), sits at the crossroads of several signaling cascades and regulates diverse cellular functions such as cell metabolism, proliferation, angiogenesis, and the suppression of apoptosis [1]. In prostate cancer, evidence strongly suggests that the hyperactivation of this pathway is primarily driven by the loss of function of the tumor suppressor PTEN [1]. For many years, developing selective Akt inhibitors proved challenging due to toxicity and complex feedback loops. However, AZD5363 (Capivasertib) has emerged as a novel, orally bioavailable, and highly potent pan-AKT inhibitor [1][3]. It is currently being extensively evaluated in clinical trials to address the unmet medical needs in advanced prostate cancer, particularly in metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC) [1][15].
2. Pharmacological Activity
Capivasertib has demonstrated notable pharmacological activity in prostate cancer, particularly when utilized in combination regimens. In a phase I dose-escalation study evaluating Capivasertib in combination with the antiandrogen enzalutamide in patients with mCRPC, the recommended phase II dose was identified as 400 mg. The study observed composite responses (defined as PSA decline ≥50%, radiological response, and/or circulating tumor cell conversion) specifically in patients harboring PTEN loss or AKT-activating mutations [1].
The efficacy of Capivasertib was further evaluated in the ProCAID trial, a phase II placebo-controlled randomized study that combined Capivasertib with docetaxel and prednisolone in mCRPC patients [1][4]. While the addition of Capivasertib to chemotherapy did not extend the primary endpoint of composite progression-free survival (cPFS) (median 7.03 vs. 6.70 months), it significantly increased the secondary endpoint of overall survival (OS), achieving a median OS of 31.15 months compared to 20.27 months for the placebo group (HR = 0.54; p = 0.01) [1].
More recently, the phase III CAPItello-281 trial investigated Capivasertib in combination with abiraterone in patients with de novo mHSPC characterized by PTEN deficiency [1][8]. This pivotal study demonstrated that the addition of Capivasertib significantly improved radiographic progression-free survival (rPFS) with a hazard ratio of 0.81 in the PTEN-deficient subgroup, thereby establishing a new biomarker-directed treatment paradigm for mHSPC [15].
3. Molecular Mechanism of Action
Capivasertib is a potent, ATP-competitive kinase inhibitor that exhibits robust activity against all three AKT isoforms (AKT1, AKT2, and AKT3) [3][10][12]. It exerts its pharmacological effect by directly binding to the ATP-binding site on the AKT kinase, which prevents the phosphorylation and subsequent activation of downstream effectors [3].
At the molecular level, the inhibition of AKT by Capivasertib reduces the phosphorylation of several key substrates, including glycogen synthase kinase 3 (GSK3), ribosomal protein S6, and the BCL2-associated agonist of cell death (BAD) [2]. This disruption severely impairs glucose metabolism and protein synthesis within the tumor cells [2]. Furthermore, Capivasertib induces the nuclear localization of critical transcription factors such as forkhead box O1 (FOXO1), FOXO3a, and p53 [2][5]. The translocation of FOXO3a to the nucleus acts as a genetic switch to upregulate the expression of target genes, including p27, FasL, and BIM, which collectively induce cell-cycle arrest and promote apoptosis [5].
4. Structure-Activity Relationship (SAR)
The core structure-activity relationship of Capivasertib is defined by its design as an ATP-competitive inhibitor [2][14]. By structurally mimicking adenosine triphosphate (ATP), Capivasertib competitively binds to the highly conserved ATP-binding pocket of the AKT kinase [3]. Because the ATP-binding domain is highly conserved across the AKT family, this specific binding modality allows the compound to act as a pan-AKT inhibitor. It effectively neutralizes the kinase activity of all three distinct AKT isoforms (AKT1, AKT2, and AKT3) without requiring isoform-specific structural variations, ensuring a comprehensive blockade of the AKT signaling node [3][10].
5. Current Limitations
The clinical application of Capivasertib is currently limited by its toxicity profile, which is characteristic of agents targeting the physiological PI3K-AKT-mTOR pathway. These on-target, off-tumor toxicities most commonly manifest as rash, hyperglycemia, diarrhea, nausea, and fatigue [1][10][15]. In the CAPItello-281 trial, rash occurred in 28% of patients and diarrhea in 22% [15]. Similarly, in the phase I study combining Capivasertib with enzalutamide, grade ≥3 adverse events included hyperglycemia (26.7%) and rash (20%) [1]. These adverse events often necessitate dose interruptions, dose reductions, or permanent treatment discontinuations, requiring rigorous patient monitoring and supportive care [10].
Additionally, efficacy limitations exist depending on the combination strategy and disease context. For instance, in the ProCAID trial, the addition of Capivasertib to docetaxel chemotherapy failed to extend the primary endpoint of composite progression-free survival in mCRPC patients, indicating that not all combination strategies yield synergistic benefits across all survival metrics [1].
6. Future Perspectives
The future development of Capivasertib in prostate cancer is heavily focused on biomarker-driven precision oncology and rational combination therapies. The success of the CAPItello-281 trial has prospectively validated PTEN deficiency as a critical predictive biomarker, supporting the routine use of PTEN testing to guide therapy selection in mHSPC [15]. A major future challenge will involve identifying additional biomarkers to better select patients who can benefit most from AKT inhibitors, potentially at even earlier stages of the disease [1].
Furthermore, because there is a well-documented reciprocal feedback regulation and crosstalk between the androgen receptor (AR) and PI3K/AKT signaling pathways, ongoing and future trials will continue to explore the combined blockade of these pathways. Combinations of Capivasertib with AR-targeted therapies, such as abiraterone or enzalutamide, hold significant promise for overcoming castration resistance and delaying disease progression in advanced prostate cancer [1][8].
